Listen to this page using ReadSpeaker
Posts tagged National Eye Institute

Dr. Eliot Berson, Pioneer in Vitamin A Therapy for Retinitis Pigmentosa, Passes Away

No one in the retinal disease research community brought more passion and commitment to his or her work than Dr. Eliot Berson. As The William F. Chatlos Professor of Ophthalmology at Harvard Medical School, he dedicated himself to clinical care and vision-saving research for people with inherited retinal diseases for five decades. In addition to being a world-renowned clinical researcher and developer of vitamin A therapy for retinitis pigmentosa, he was beloved by his patients and their families for his hopeful and encouraging attitude toward their challenging, vision-robbing conditions.
Continue Reading…

FFB-CRI Leads Effort to Identify Outcome Measures for Therapies in Clinical Trials

Side view of a retina as captured by SD-OCT. The EZ Width is the yellow line extending between the arrows. The patient has advanced RP with significant loss of peripheral vision.

A key to gaining regulatory approval for an emerging retinal-disease therapy is quickly and accurately demonstrating that it saves or restores vision in a clinical trial. Though the goal sounds simple enough, proving that a potential treatment is working is actually difficult. That’s because commonly used measures of visual function — including visual acuity and visual fields — are not always reliable for evaluating vision changes in many people with inherited retinal conditions.

For example, visual acuity can remain stable for someone with retinitis pigmentosa (RP) for decades. While visual fields for people with RP contract over time, measuring the changes objectively is challenging; results for a given patient can vary significantly, even for the same patient on the same day.
Continue Reading…

ARVO 2015 Highlight: The National Eye Institute Invests $4 Million in Audacious-Goals Research

future of retinal researchThe National Eye Institute’s (NEI) establishment of its Audacious Goals in 2013 was a watershed moment in the drive to cure blinding retinal diseases. The mission of the program—to regenerate the neurons and neural connections in the eye and visual system—is synonymous with the Foundation’s mission to eradicate retinal diseases. Most important, it means that the NEI is making significant investments in research that will benefit people with retinal conditions, such as retinitis pigmentosa, Usher syndrome, Stargardt disease, and age-related macular degeneration.
Continue Reading…

Israeli Research Group Receives $1.33 Million to Advance Stem Cell Treatment

Dr. Benjamin Reubinoff

I was heartened to just learn that researchers from the Hadassah-Hebrew Medical Center in Jerusalem are receiving a $1.33 million grant from the Israeli government to advance their development of a stem cell treatment for people with dry age-related macular degeneration (AMD Hadassah is also funded by the Foundation Fighting Blindness. We are providing the group with a three-year, $300,000 grant for development of stem cell therapies.

Continue Reading…